Evaluation of the effectiveness of combined antihyperlipidemic therapy with the use of plant saponins in patients with acute myocardial infarction
Authors:
Company:
1 Russian National Research Medical University named after N.I. Pirogov, Moscow, Russian Federation
2 City Clinical Hospital № 1 named after N.I. Pirogov, Moscow, Russian Federation
3 City Clinical Hospital № 13, Moscow, Russian Federation
For correspondence: Sign in or register.
Type: Original articles
DOI:
Received / Accepted: 09.09.2024 / 27.09.2024
Abstract
Goal. To evaluate the effectiveness of two variants of combined antihyperlipidemic therapy in achieving the target parameters of the blood lipid profile in patients who have undergone ACS.
Material and methods. The study included 60 patients who underwent ACS and did not reach the target LDL values 1 month after discharge from the hospital on the background of atorvastatin monotherapy (60 mg/day). Patients were divided into 3 groups: first Ezetimibe 10 mg/day + Atorvastatin 60 mg/day, the second Vasosponine 400 mg/day + Atorvastatin 60 mg/day, control (KG) – monotherapy with atorvastatin 60 mg/day. The observation time is 6 months.
Results. By the end of the study, a comparable reduction of OHS was achieved in the main groups: in the first group – 30.1%, in the second – 33.0%. Reduction of LDL-C after 6 months of therapy in the first group – 49.2%, in the second – 54.1%; in KG – 21.1%. In the main groups of patients, a significant tendency to increase HDL-C in blood plasma was revealed. Reduction of TG – 10.2% (p = 0.000003) in the first group, in the second and KG – 14.2% (p < 0.001) was shown. In the first group, a significant decrease in KA was revealed – 52.2%, in the second – 54.7%, in KG – 19.2%.
Conclusion. A comparative analysis of the effectiveness of two variants of combined antiatherogenic therapy showed their comparable effectiveness. The combination of ezetimibe + atorvastatin is characterized by a tendency to an earlier onset of hypolipidemic action, while the combination of vasosponine + atorvastatin showed a tendency to a later, but more pronounced hypolipidemic effect.
References
- Kontsevaya A.V., Balanova Yu.A., Isaeva A.E., Deev A.D., Kapustina A.V., Muromtseva G.A., et al. on behalf of the participants of the ESSAY-RF study. Medical treatment and temporary disability of the population aged 50-64 years according to the epidemiological study ESSE-RF. Rational Pharmacotherapy in Cardiology. 2017; 13 (4): 432–442 (in Russ.). DOI: 10.20996/1819-6446-2017-13-4-432-442
- Healthcare in Russia. 2021: Stat.sat./Rosstat. Moscow; 2021 (in Russ.).
- Shalnova S.A., Deev A.D. Trends in mortality in Russia at the beginning of the XXI century (according to official statistics). Cardiovascular therapy and prevention. 2011; 10 (6): 5–10 (in Russ.).
- Sichinava D.P., Kalaijyan E.P., Martsevich S.Yu., Kutishenko N.P. Characteristics of patients who suffered acute myocardial infarction included in the Profile-IM register. CardioSomatics. 2017; 1: 5–88 (in Russ.).
- Guidelines ESC/EAS for the treatment of dyslipidemia: modification lipids to reduce cardiovascular risk. Russian Journal of Cardiology. 2020; 25 (5): 70–145 (in Russ.). DOI: 10.15829/1560-4071-2020-3826
- Boytsov S.A., Pogosova N.V., Bubnova M.G., Drapkina O.M., Gavrilova N.E., Yeganyan R.A., et al. Cardiovascular prevention 2017. National guidelines. Russian Journal of Cardiology. 2018; 6: 7–122 (in Russ.). DOI: 10.15829/1560-4071-2018-6-7-122
- Kukharchuk V.V., Ezhov M.V., Sergienko I.V., Arabidze G.G., Balakhonova T.V., Gurevich V.S. et al. Eurasian Association of Cardiology (EAC) / Russian National Atherosclerosis Society (RNAS) Guidelines for the diagnosis and correction of dyslipidemia for the prevention and treatment of atherosclerosis (2020). Eurasian Heart Journal. 2020; 2: 6–29 (in Russ.). DOI: 10.38109/2225-1685-2020-2-6-29
- Gusev A.A. Comparative study of biological properties of saponins. Veterinary medicine. 1980; 1: 26 (in Russ.).
- Turgeon R.D., Pearson G.J. Proprotein convertase subtilisin/kexin type 9 inhibitors for reduction of cardiovascular events. Am. J. Health Syst. Pharm. 2018; 75 (11): 747–754. DOI: 10.2146/ajhp170707
- Saborowski M., Dolle M., Manns M.P., Leitolf H., Zender S. Lipid-lowering therapy with PCSK9-inhibitors in the management of cardiovascular high-risk patients: Effectiveness, therapy adherence and safety in a real world cohort. Cardiol. J. 2018; 25 (1): 32–41. DOI:10.5603/CJ.a2017.0137
- Oyama K., Giugliano R.P., Tang M., Murphy S.A., Sabatine M.S., Bergmark B.A. Effect of evolocumab on acute arterial events across all vascular territories: results from the FOURIER trial. Eur. Heart J. 2021; 42: 4821–4829. DOI: 10.1093/eurheartj/ehab604
- Ray K.K., Wright R.S., Kallend D., Koenig W., Leiter L.A., Raal F.J. et al., on behalf of the ORION-10 and ORION-11 investigators. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N. Engl. J. Med. 2020; 382: 1507–1519. DOI: 10.1056/NEJMoa1912387
- Nissen S.E., Stroes E., Dent-Acosta R.E., Rosenson R.S., Lehman S., Sattar N. et al.; Gauss-3 Investigators. Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial. JAMA. 2016; 315: 1580– 1590. DOI: 10.1001/jama.2016.3608
- Bogdanov A.R., Pyko M.E., Pyko A.A. Possibilities of residual dyslipidemia correction in patients with multifocal atherosclerosis, who are receiving optimal statin therapy. Consilium Medicum. 2020; 22 (1): 54–60 (in Russ.). DOI: 10.26442/20751753.2020.1.200057
- Bogdanov A.R., Pyko M.E., Romanova T.A., Fedulaev Yu.N. The influence of plant saponins on the elasticity parameters of the great arteries in patients with multifocal atherosclerosis. CardioSomatics. 2021; 12 (1): 41–47 (in Russ.). DOI: 10.26442/22217185.2021.1.200631
